EUVIMEDEUVIMED entdecken
Crossref

Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients

Takeshi Nakamura, Tomoyoshi Miyamoto, Daisuke Tanada, Rie Nishii, Saki Okamura, Takae Inui, Yoko Doi, Kuniyoshi Tanaka, Mina Yanai, Munetaka Hirose, Takeshi Kimura

Journal of Opioid Management · 2024

DOI: 10.5055/jom.0859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Opioid Management, 2024. Verfasst von Takeshi Nakamura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Palliative Care Center, Hyogo Medical University Hospital, Hyogo, Japan. ORCID: https://orcid.org/0009-0007-0978-9019. Hauptthemen laut MEDLINE: Tapentadol, Delirium, Analgesics, Opioid, Duloxetine Hydrochloride. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Tapentadol causes fewer gastrointestinal adverse events than other potent opioid analgesics because of its low affinity for opioid receptors; however, development of symptoms related to central nervous system disorders, including delirium, has not been well-studied. This study aimed to identify the factors that influence the development of delirium after initiation of tapentadol therapy in hospitalized patients with cancer.

Design

Retrospective study. Setting/patients: Among 93 patients, for whom treatment using tapentadol was initiated between December 1, 2017, and November 30, 2019, at a single center in Japan, 86 met the inclusion criteria and were enrolled in this study. Main outcome measures: Delirium occurring within 2 weeks of initiation of the tapentadol treatment was diagnosed by a physician or nurse. Patient background information was obtained, including data on age, sex, medical history, adverse events, starting dose of tapentadol, and concomitant medications.

Results

Age ≥ 67 years, male sex, somnolence after initiation of tapentadol therapy, dose of ≥300 mg/day at the beginning of tapentadol therapy, switching from potent opioids, and concomitant use of duloxetine were associated with delirium occurring after tapentadol therapy initiation.

Conclusions

Among the factors associated with the incidence of delirium after the initiation of tapentadol therapy, patients whose starting dose of tapentadol was 300 mg/day or higher and those receiving concomitant duloxetine, a serotoninnoradrenaline reuptake inhibitor, were at high risk of developing delirium. These findings will help healthcare providers, including pharmacists, in development of treatment plans for preventing delirium when initiating tapentadol therapy in patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TapentadolDeliriumAnalgesics, OpioidDuloxetine HydrochlorideNeoplasmsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedCancer PainAged, 80 and overJapanAdult

Substanzen

TapentadolAnalgesics, OpioidDuloxetine Hydrochloride

Autor:innen und Institutionen

  • Department of Pharmacy, Palliative Care Center, Hyogo Medical University Hospital, Hyogo, Japan. ORCID: https://orcid.org/0009-0007-0978-9019.
  • School of Pharmacy, Hyogo Medical University, Hyogo, Japan. ORCID: https://orcid.org/0000-0001-5593-1046.
  • Department of Palliative Medicine, Hannan Chuo Hospital, Osaka, Japan.
  • Palliative Care Center, Department of Neuropsychiatry, Hyogo Medical University Hospital, Hyogo, Japan.
  • Department of Pharmacy, Palliative Care Center, Hyogo Medical University Hospital, Hyogo, Japan.
  • Palliative Care Center, Hyogo Medical University Hospital, Hyogo, Japan.

Zitieren

APA

Nakamura, T., Miyamoto, T., Tanada, D., Nishii, R., Okamura, S., Inui, T., Doi, Y., Tanaka, K., Yanai, M., Hirose, M., & Kimura, T. (2024). Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients. Journal of Opioid Management. https://doi.org/10.5055/jom.0859

Vancouver

Nakamura T, Miyamoto T, Tanada D, Nishii R, Okamura S, Inui T, et al. Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients. Journal of Opioid Management. 2024. doi:10.5055/jom.0859

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Takeshi and Miyamoto, Tomoyoshi and Tanada, Daisuke and Nishii, Rie and Okamura, Saki and Inui, Takae and Doi, Yoko and Tanaka, Kuniyoshi and Yanai, Mina and Hirose, Munetaka and Kimura, Takeshi},
  title = {Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients},
  journal = {Journal of Opioid Management},
  year = {2024},
  doi = {10.5055/jom.0859}
}
Kostenlos starten →